Hepatology News and Research RSS Feed - Hepatology News and Research

Hepatology is the branch of medicine that incorporates study of liver, gallbladder, biliary tree and pancreas as well as management of their disorders.
High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases, according to new research published in the journal Hepatology. These findings could result in new ways to treat cholestatic liver diseases, a condition that impairs the movement of bile, the fluid produced by the liver to digest fats. [More]
Clinical study shows sitagliptin drug not effective in treating NAFLD

Clinical study shows sitagliptin drug not effective in treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. [More]
Celiac disease more common among Americans with Punjabi ancestry, study shows

Celiac disease more common among Americans with Punjabi ancestry, study shows

About 1.8 million Americans have celiac disease, an immune-based condition brought on by the consumption of gluten in genetically susceptible patients. Among patients diagnosed with celiac disease by small intestinal biopsy in the U.S., those from the Punjab region of India have the highest rates of disease, according to new research published in Clinical Gastroenterology and Hepatology,1 the official clinical practice journal of the American Gastroenterological Association. [More]
Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. [More]
CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

Cellular and Molecular Gastroenterology and Hepatology is committed to publishing impactful digestive biology research covering a broad spectrum of themes in GI, hepatology and pancreatology. We wanted to share two new CMGH articles, which both offer important insight into future interventions for chronic conditions. [More]
Additional water or milk intake changes dietary pattern in overweight children

Additional water or milk intake changes dietary pattern in overweight children

New research by Andersen et al, published in the International Journal of Food Sciences and Nutrition, may have an impact on the sugar tax debate. The research team observed overall changes in dietary patterns in overweight children, including a decrease in consumption of sugary drinks, when additional water or milk is added to their diet. [More]
HBcrAg may predict HCC development

HBcrAg may predict HCC development

Research suggests a role for hepatitis B core-related antigen in the prediction of hepatocellular carcinoma development in nucleos(t)ide analogue treatment-naïve patients with chronic hepatitis B virus infection. [More]
WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

WFA+-M2BP levels linked to liver fibrosis, HCC progression in chronic HBV

Japanese researchers have found that serum levels of glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein are a useful marker of not only the degree of liver fibrosis, but also progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Serum marker may flag liver fibrosis in chronic HBV

Serum marker may flag liver fibrosis in chronic HBV

Serum levels of Wisteria floribunda agglutinin-positive Mac-2-binding protein may reflect the severity of liver fibrosis in patients with chronic hepatitis B virus infection, say researchers. [More]
Regular aspirin use may help reduce risk of bile duct cancer

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted. [More]
Non-invasive test to diagnose EoE could replace need for repeated endoscopy

Non-invasive test to diagnose EoE could replace need for repeated endoscopy

A non-invasive test to diagnose and monitor an inflammatory disease that injures the esophagus - called eosinophilic esophagitis or EoE - would replace the need for repeated endoscopy for a growing number of children and adults with this relatively new condition. [More]
Aspirin use linked with reduced risk of developing bile duct cancer

Aspirin use linked with reduced risk of developing bile duct cancer

A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology. [More]
New therapy strategy for liver disease shows initial measureable success with norUrso

New therapy strategy for liver disease shows initial measureable success with norUrso

The new therapy strategy for primary sclerosing cholangitis, a liver disease that at present still cannot be cured with medication, shows initial measureable success with the nor-ursodeoxycholic acid (norUrso). [More]
VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12). [More]
Dynamic HBsAg measurements predict HBV inactivity

Dynamic HBsAg measurements predict HBV inactivity

In patients with hepatitis B e antigen-negative chronic hepatitis B virus infection, repeated measurement of hepatitis B surface antigen during long-term follow-up can help identify those with inactive virus, suggests a chart review. [More]
Hepatitis C treatment can be provided safely, effectively within community-based setting

Hepatitis C treatment can be provided safely, effectively within community-based setting

A new study, presented today, demonstrates treatment for Hepatitis C can be provided safely and effectively within a community-based and non-specialist setting. This illustrates the potential for alternative providers to ease pressure on currently overburdened specialists. The study, sponsored by the National Institutes of Health, was presented at The International Liver Congress 2016 in Barcelona, Spain. [More]
Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Daily dose of coffee could help reverse non-alcoholic fatty liver disease

Adding coffee to the diet of people with non-alcoholic fatty liver disease (NAFLD) could help reverse the condition, according to a new study conducted in mice presented at The International Liver Congress 2016 in Barcelona, Spain. [More]
Hospitals could reduce burden of alcohol-related liver disease through universal screening procedure

Hospitals could reduce burden of alcohol-related liver disease through universal screening procedure

The growing burden of alcohol-related liver disease (ARLD) could be reduced if hospitals introduced a simple universal screening procedure for those attending acute and emergency hospital settings, according to a new study shared today at The International Liver Congress in Barcelona, Spain. [More]
HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a 'high rate' of re-developing their illness. [More]
Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV). [More]
Advertisement